SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) announced today a multi-million dollar agreement with one of the top five pharmaceutical companies for the purchase and installation of a multi-component genetic analysis system. Depending on the Illumina arrays being processed, this system will be capable of generating over 45 million genotypes per day, and will represent a core support facility for the company’s global research teams. The Illumina genetic analysis system will be capable of running both genotyping and gene expression applications and will include a number of scanners and robotic components for automated sample and array processing.
